| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University Medical Center, Stanford, CA.
Correspondence to: Thomas A. Raffin, MD, FCCP, Professor and Chief, Division of Pulmonary and Critical Care Medicine, Stanford University Medical Center, H-3151, Stanford, CA 94305-5236; tar@leland.stanford.edu
Anthrax, a disease of great historical interest, is once again making headlines as an agent of biological warfare. Bacillus anthracis, a rod-shaped, spore-forming bacterium, primarily infects herbivores. Humans can acquire anthrax by agricultural or industrial exposure to infected animals or animal products. More recently, the potential for intentional release of anthrax spores in the environment has caused much concern. The common clinical manifestations of anthrax are cutaneous disease, pulmonary disease from inhalation of anthrax spores, and GI disease. The course of inhalational anthrax is dramatic, from the insidious onset of nonspecific influenza-like symptoms to severe dyspnea, hypotension, and hemorrhage within days of exposure. A rapid decline, culminating in septic shock, respiratory distress, and death within 24 h is not uncommon. The high mortality seen in inhalational anthrax is in part due to delays in diagnosis. Classic findings on the chest radiograph include widening of the mediastinum as well as pleural effusions. Pneumonia is less common; key pathologic manifestations include severe hemorrhagic mediastinitis, diffuse hemorrhagic lymphadenitis, and edema. Diagnosis requires a high index of suspicion. Treatment involves supportive care in an intensive care facility and high doses of penicillin. Resistance to third-generation cephalosporins has been noted. Vaccines are currently available and have been shown to be effective against aerosolized exposure in animal studies.
Key Words: anthrax • Bacillus species • inhalational anthrax • mediastinal hemorrhage • mediastinal widening
This article has been cited by other articles:
|
|
 |
|
  Inhalation Anthrax Associated With Dried Animal Hides--Pennsylvania and New York City, 2006 JAMA, May 3, 2006; 295(17): 1991 - 1993. [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Biagini, D. L. Sammons, J. P. Smith, B. A. MacKenzie, C. A. F. Striley, J. E. Snawder, S. A. Robertson, and C. P. Quinn Rapid, sensitive, and specific lateral-flow immunochromatographic device to measure anti-anthrax protective antigen immunoglobulin g in serum and whole blood. Clin. Vaccine Immunol., May 1, 2006; 13(5): 541 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Firoved, G. F. Miller, M. Moayeri, R. Kakkar, Y. Shen, J. F. Wiggins, E. M. McNally, W.-J. Tang, and S. H. Leppla Bacillus anthracis Edema Toxin Causes Extensive Tissue Lesions and Rapid Lethality in Mice Am. J. Pathol., November 1, 2005; 167(5): 1309 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Brittingham, G. Ruthel, R. G. Panchal, C. L. Fuller, W. J. Ribot, T. A. Hoover, H. A. Young, A. O. Anderson, and S. Bavari Dendritic Cells Endocytose Bacillus anthracis Spores: Implications for Anthrax Pathogenesis J. Immunol., May 1, 2005; 174(9): 5545 - 5552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Fowler, G. D. Sanders, D. M. Bravata, B. Nouri, J. M. Gastwirth, D. Peterson, A. G. Broker, A. M. Garber, and D. K. Owens Cost-Effectiveness of Defending against Bioterrorism: A Comparison of Vaccination and Antibiotic Prophylaxis against Anthrax Ann Intern Med, April 19, 2005; 142(8): 601 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Wood, B. DeFranco, M. Ripple, M. Topiel, C. Chiriboga, V. Mani, K. Barry, D. Fowler, H. Masur, and L. Borio Inhalational Anthrax: Radiologic and Pathologic Findings in Two Cases Am. J. Roentgenol., October 1, 2003; 181(4): 1071 - 1078. [Full Text] [PDF]
|
|
|
|
|
|
N. Hupert, G. M.L. Bearman, A. I. Mushlin, and M. A. Callahan Accuracy of Screening for Inhalational Anthrax after a Bioterrorist Attack Ann Intern Med, September 2, 2003; 139(5_Part_1): 337 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. Chapman, G. F. Cooper, P. Hanbury, B. E. Chapman, L. H. Harrison, and M. M. Wagner Creating a Text Classifier to Detect Radiology Reports Describing Mediastinal Findings Associated with Inhalational Anthrax and Other Disorders J. Am. Med. Inform. Assoc., September 1, 2003; 10(5): 494 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Boyaka, A. Tafaro, R. Fischer, S. H. Leppla, K. Fujihashi, and J. R. McGhee Effective Mucosal Immunity to Anthrax: Neutralizing Antibodies and Th Cell Responses Following Nasal Immunization with Protective Antigen J. Immunol., June 1, 2003; 170(11): 5636 - 5643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Meyer Neurologic Complications of Anthrax: A Review of the Literature Arch Neurol, April 1, 2003; 60(4): 483 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R C Spencer Bacillus anthracis J. Clin. Pathol., March 1, 2003; 56(3): 182 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, J. Succi, F. C. Tenover, and T. M. Koehler {beta}-Lactamase Genes of the Penicillin-Susceptible Bacillus anthracis Sterne Strain J. Bacteriol., February 1, 2003; 185(3): 823 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fouet, K. L. Smith, C. Keys, J. Vaissaire, C. Le Doujet, M. Levy, M. Mock, and P. Keim Diversity among French Bacillus anthracis Isolates J. Clin. Microbiol., December 1, 2002; 40(12): 4732 - 4734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Drago, E. De Vecchi, A. Lombardi, L. Nicola, M. Valli, and M. R. Gismondo Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates J. Antimicrob. Chemother., December 1, 2002; 50(6): 1059 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Bell, J. R. Uhl, T. L. Hadfield, J. C. David, R. F. Meyer, T. F. Smith, and F. R. Cockerill III Detection of Bacillus anthracis DNA by LightCycler PCR J. Clin. Microbiol., August 1, 2002; 40(8): 2897 - 2902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. White Chemical and biological weapons. Implications for anaesthesia and intensive care{dagger} Br. J. Anaesth., August 1, 2002; 89(2): 306 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-D. Cavallo, F. Ramisse, M. Girardet, J. Vaissaire, M. Mock, and E. Hernandez Antibiotic Susceptibilities of 96 Isolates of Bacillus anthracis Isolated in France between 1994 and 2000 Antimicrob. Agents Chemother., July 1, 2002; 46(7): 2307 - 2309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Krol, M. Uszynski, E. H. Dillon, M. Farhad, S. C. Machnicki, B. Mina, and L. M. Rothman Dynamic CT Features of Inhalational Anthrax Infection Am. J. Roentgenol., May 1, 2002; 178(5): 1063 - 1066. [Full Text] [PDF]
|
|
|
|
|
|
B. Mina, J. P. Dym, F. Kuepper, R. Tso, C. Arrastia, I. Kaplounova, H. Faraj, A. Kwapniewski, C. M. Krol, M. Grosser, et al. Fatal Inhalational Anthrax With Unknown Source of Exposure in a 61-Year-Old Woman in New York City JAMA, February 20, 2002; 287(7): 858 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Weir Anthrax: of bison and bioterrorism Can. Med. Assoc. J., September 1, 2000; 163(5): 608 - 608. [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Earls, D. Cerva Jr, E. Berman, J. Rosenthal, N. Fatteh, P. P. Wolfe, R. Clayton, C. Murphy, D. Pauze, T. Mayer, et al. Inhalational Anthrax after Bioterrorism Exposure: Spectrum of Imaging Findings in Two Surviving Patients Radiology, February 1, 2002; 222(2): 305 - 312. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
